Prenetics Global Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.52
- Today's High:
- $0.56
- Open Price:
- $0.56
- 52W Low:
- $0.42
- 52W High:
- $4.11
- Prev. Close:
- $0.52
- Volume:
- 39866
Company Statistics
- Market Cap.:
- $93.74 million
- Book Value:
- 1.437
- Revenue TTM:
- $201.42 million
- Operating Margin TTM:
- -46.82%
- Gross Profit TTM:
- $131.55 million
- Profit Margin:
- -83.63%
- Return on Assets TTM:
- -25.59%
- Return on Equity TTM:
- 0%
Company Profile
Prenetics Global Ltd had its IPO on 2022-05-18 under the ticker symbol PRE.
The company operates in the Healthcare sector and Diagnostics & Research industry. Prenetics Global Ltd has a staff strength of 400 employees.
Stock update
Shares of Prenetics Global Ltd opened at $0.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.52 - $0.56, and closed at $0.52.
This is a +0.19% increase from the previous day's closing price.
A total volume of 39,866 shares were traded at the close of the day’s session.
In the last one week, shares of Prenetics Global Ltd have slipped by -3.87%.
Prenetics Global Ltd's Key Ratios
Prenetics Global Ltd has a market cap of $93.74 million, indicating a price to book ratio of 0 and a price to sales ratio of 1.48.
In the last 12-months Prenetics Global Ltd’s revenue was $201.42 million with a gross profit of $131.55 million and an EBITDA of $-89784184. The EBITDA ratio measures Prenetics Global Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Prenetics Global Ltd’s operating margin was -46.82% while its return on assets stood at -25.59% with a return of equity of 0%.
In Q1, Prenetics Global Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 80.8%.
Prenetics Global Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Prenetics Global Ltd’s profitability.
Prenetics Global Ltd stock is trading at a EV to sales ratio of 1.535 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 1.48.
Prenetics Global Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $307.98 million
- Total Liabilities
- $57.20 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Prenetics Global Ltd ended 2024 with $307.98 million in total assets and $0 in total liabilities. Its intangible assets were valued at $307.98 million while shareholder equity stood at $237.06 million.
Prenetics Global Ltd ended 2024 with $0 in deferred long-term liabilities, $57.20 million in other current liabilities, 13698.00 in common stock, $0 in retained earnings and $32.83 million in goodwill. Its cash balance stood at $146.66 million and cash and short-term investments were $164.20 million. The company’s total short-term debt was $2,882,933 while long-term debt stood at $0.
Prenetics Global Ltd’s total current assets stands at $242.14 million while long-term investments were $677339.00 and short-term investments were $17.54 million. Its net receivables were $48.58 million compared to accounts payable of $7.29 million and inventory worth $4.86 million.
In 2024, Prenetics Global Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Prenetics Global Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.52
- 52-Week High
- $4.11
- 52-Week Low
- $0.42
- Analyst Target Price
- $6.9
Prenetics Global Ltd stock is currently trading at $0.52 per share. It touched a 52-week high of $4.11 and a 52-week low of $4.11. Analysts tracking the stock have a 12-month average target price of $6.9.
Its 50-day moving average was $0.69 and 200-day moving average was $1.09 The short ratio stood at 1.08 indicating a short percent outstanding of 0%.
Around 2779.8% of the company’s stock are held by insiders while 737.4% are held by institutions.
Frequently Asked Questions About Prenetics Global Ltd
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company’s products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.